Taiwan's Biotech Sector Plan Stalled By Funding Limitations, Wary Investors
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Taiwan's aspirations to become a regional biotech powerhouse have been delayed in the last year by overly stringent requirements and a lack of professionals to undertake two key portions of a four-part industry development blueprint
You may also be interested in...
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
Taiwan Investing Millions To Become Regional Pharma R&D Hub And Gateway To Mainland China
HONG KONG - As part of a four-part plan to develop biotech into its next "trillion-dollar industry," Taiwan is investing hundreds of millions of dollars into the sector and developing specialized science parks and clusters